Feasibility and effects of Whole-body vibration training in pediatric cancer patients undergoing chemotherapy
Not Applicable
- Conditions
- pediatric cancerC00-D48Neoplasms
- Registration Number
- DRKS00008578
- Lead Sponsor
- Deutsche Sporthochschule Köln, Insstitut für Kreislaufforschung und Sportmedizin, Abteilung molekulare und zelluläreSportmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
oncological disease, inpatient medical treatment including chemotherapy, age between 4 and 17 years, baseline testing before or 7-14 days after finishing first chemotherapy, medical clearance (approval of the treating physician), written informed consent
Exclusion Criteria
prior oncological disease, palliative care, instable osteolysis of lower extremity or pelvis, diagnosed osteonecrosis of lower extremity or pelvis, fracture of lower extremity or pelvis within the last 6 months prior to baseline testing, osteosynthesis, implants in lower extremity, Cerebral metastases, acute prolapse, epilepsy, pregnancy, mental health conditions that do not allow participation in training and/or testing, insufficient German language skills
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility of Whole-body vibration training for pediatric cancer patients undergoing chemotherpy is assessed by drop-Out, compliance to training and adverse events.<br>The study is defined feasible, if (1) less than 50% of all study participants are lost due to drop-out before t1(endpoint) and (2) compliance to training sessions (2x/week) is at least 50%. Adverse events are defined as declines in health that are caused by the whole-body vibration intervention. All Adverse events are documented.<br>
- Secondary Outcome Measures
Name Time Method Effects of Whole-body vibration training for pediatric cancer patients undergoing chemotherapy on active dorsiflexion range of motion (DF-ROM, goniometer), on isometric dorsiflexion strength (DF-strength, hand-held dynamometer), on mobility (Timed-Up-And-Go Test), on gait (Dartfish Video Gait Analysis) and on physical activity (PA, activity questionnaire) are analysed. Secondary endpoints are assessed before (or 7-14 days after finishing the first chemotherpaie, t0, baseline), after (t1, endpoint) and three month (t2, follow-up) after in-patient medical treatment. Middle points are assessed every three months.<br><br><br>